Yahoo Web Search

Sign In

Search results

  1. medicine.yale.edu › adrcYale Alzheimer’s Disease Research Center < Alzheimer's ...

    Alzheimer’s disease is the 6th leading cause of death in the United States. An estimated 5.7 million Americans of all ages have Alzheimer's disease, with more than 77,000 in the state of Connecticut alone. The Yale Alzheimer's Disease Research Center is funded by the National Institutes of Health, National Institute on Aging (NIA).

  2. medicine.yale.edu › psychiatry › alzheimersAlzheimer's Disease Research Unit - Yale School of Medicine

    • BAN2401 For Individuals at Risk For Alzheimer’s Dementia
    • CT1812 For Early Alzheimer’s Disease
    • Aducanumab For Early Alzheimer’s Disease
    • Cvl-871 For The Treatment of Dementia-Related Apathy

    A stage of “preclinical Alzheimer’s disease” has recently been defined based on biomarker evidence of amyloid-β pathology before the stage of clinical symptoms. Clinically “normal” older individuals with elevated Aβ pathology (by PET scan) are at increased risk for cognitive decline and progression to Alzheimer’s dementia. BAN2401 is a humanized mo...

    See full list on medicine.yale.edu

    CT1812 is a sigma-2 receptor modulator that is thought to displace and reduce binding of toxic beta-amyloid oligomers to neuronal synapses, with the potential to provide clinical benefit in Alzheimer’s disease. This is a Phase 2, double-blind, placebo-controlled study designed to evaluate the efficacy, safety, and tolerability of CT1812 in particip...

    See full list on medicine.yale.edu

    Aducanumab is a human monoclonal antibody that is directed against the amyloid-β protein. Aducanumab was approved by the US FDA as a treatment for Alzheimer’s disease under the accelerated approval pathway based on aducanumab’s reduction in brain amyloid coupled with evidence that reduction in brain amyloid is reasonably likely to predict clinical ...

    See full list on medicine.yale.edu

    Apathy is among the most prevalent and disabling neuropsychiatric symptoms in individuals with dementia. CVL-871 is a dopamine D1/D5 receptor partial agonist that may normalize impaired dopamine signaling in brain regions that control reward and motivation and thus be useful for the treatment of apathy. This is a Phase 2a, double-blind, placebo-con...

    See full list on medicine.yale.edu

  3. People also ask

  4. medicine.yale.edu › adrc › clinicalClinical Trials < Alzheimer's Disease Research Center (ADRC)

    Clinical trials for individuals with Alzheimer's disease and individuals at risk for future Alzheimer's disease symptoms are administered through the Alzheimer's Disease Research Unit (ADRU), One Church Street, 8th Floor, New Haven, CT 06510.

  5. www.ynhh.org › conditions › alzheimers-dementiaAlzheimer’s & Dementia – Yale New Haven Hospital

    The Yale Alzheimer's Disease Research Center (ADRC) is one of only a few Alzheimer’s disease research centers across the country designated and funded by the National Institute on Aging of the National Institutes of Health. The ADRC conducts clinical research in the treatment, neuroimaging and genetics of Alzheimer’s disease and healthy aging.

  6. Videos

    View all

  1. Searches related to What is the Yale Alzheimer's Disease Research Center?

    what is the yale alzheimer's disease research center pittsburghalzheimer's disease research
    what is the yale alzheimer's disease research center adrc what is the yale alzheimer's disease research center clarksburg md
    what is the yale alzheimer's disease research center upmcwhat is the yale alzheimer's disease research center mayo clinic
    what is the yale alzheimer's disease research center albany nywhat is the yale alzheimer's disease research center new york
  2. People also search for